Trial Profile
A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Cancer metastases; Duodenal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms REMINET
- 07 Sep 2022 Status changed from discontinued to completed according to results published in the European Journal of Cancer
- 07 Sep 2022 Results assessing lanreotide autogel 120 mg (LAN) as maintenance treatment after at least 2 months of first-line treatment (L1) in aggressive G1-G2 DP-NET published in the European Journal of Cancer
- 07 Sep 2021 Status changed from completed to discontinued.